Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
With EU knockback laquinimod's irrelevance is all but assured | Evaluate
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis | NEJM
CONFIDENTIAL DRAFT: Failure Scenario (PEP Not Achieved)
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Dark horse laquinimod reveals potential as MS pill | Evaluate
Laquinimod sodium (ABR-215062 sodium) | Immunomodulator | MedChemExpress
First patient enrolled in Phase II study evaluating laquinimod
Active Biotech regains rights of laquinimod from Teva
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Teva & Active Biotech Press Release: November 4, 2014
Meet the Compound: Laquinimod – HD Insights
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
Laquinimod | C19H17ClN2O3 - PubChem
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Teva drops development of laquinimod - PharmaTimes
